These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Phenelzine efficacy in refractory social anxiety disorder: a case series. Aarre TF Nord J Psychiatry; 2003; 57(4):313-5. PubMed ID: 12888407 [TBL] [Abstract][Full Text] [Related]
45. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder. Alpert JE; Franznick DA; Hollander SB; Fava M J Clin Psychiatry; 2004 Aug; 65(8):1069-75. PubMed ID: 15323591 [TBL] [Abstract][Full Text] [Related]
46. Chronic depression: response to placebo, imipramine, and phenelzine. Stewart JW; McGrath PJ; Quitkin FM; Rabkin JG; Harrison W; Wager S; Nunes E; Ocepek-Welikson K; Tricamo E J Clin Psychopharmacol; 1993 Dec; 13(6):391-6. PubMed ID: 8120152 [TBL] [Abstract][Full Text] [Related]
47. A comparison of phenelzine and imipramine in depressed inpatients. Davidson JR; McLeod MN; Turnbull CD; Miller RD J Clin Psychiatry; 1981 Oct; 42(10):395-7. PubMed ID: 7026542 [TBL] [Abstract][Full Text] [Related]
48. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity. Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721 [TBL] [Abstract][Full Text] [Related]
50. The effects of bifemelane hydrochloride on depressive illness of the elderly. Yamagami S; Koide S; Mui K; Perk S; Hirayama E; Kioka T; Soejima K; Inoue K; Nishiwaki S Int J Clin Pharmacol Res; 1995; 15(1):1-7. PubMed ID: 7490169 [TBL] [Abstract][Full Text] [Related]
51. Bulimia and monoamine oxidase inhibitors: a predictor study. Hardy BW; Waller DA; Orsulak PJ Tex Med; 1985 Oct; 81(10):39-42. PubMed ID: 3904070 [No Abstract] [Full Text] [Related]
52. Efficacy of phenelzine in geriatric depression. Lazarus LW; Groves L; Gierl B; Pandey G; Javaid JI; Lesser J; Ha YS; Davis J Biol Psychiatry; 1986 Jun; 21(7):699-701. PubMed ID: 3708040 [No Abstract] [Full Text] [Related]
53. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city]. Mouchabac S; Ferreri M; Cabanac F; Bitton M Encephale; 2003; 29(5):438-44. PubMed ID: 14615693 [TBL] [Abstract][Full Text] [Related]
54. Plasma levels of catecholamines and dihydroxyphenylglycol during antidepressant drug treatment. Robinson DS; Johnson GA; Nies A; Corcella J; Cooper TB; Albright D; Howard D J Clin Psychopharmacol; 1983 Oct; 3(5):282-7. PubMed ID: 6355207 [TBL] [Abstract][Full Text] [Related]
55. [Blood platelet MAO activity in endogenous depressive syndrome]. Puzyński S; Hauptmann M; Załuska M Psychiatr Pol; 1980; 14(6):575-80. PubMed ID: 7232599 [No Abstract] [Full Text] [Related]
56. Defining the boundaries of atypical depression. Quitkin FM; Harrison W; Liebowitz M; McGrath P; Rabkin JG; Stewart J; Markowitz J J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):19-21. PubMed ID: 6376482 [TBL] [Abstract][Full Text] [Related]
58. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831 [TBL] [Abstract][Full Text] [Related]